Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.
about
Polypharmacy patterns: unravelling systematic associations between prescribed medicationsA cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trialsManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.Bronchodilators use in patients with COPD.Chronic Condition Clusters and Polypharmacy among Adults.The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.Adherence and non-adherence to treatments: focus on pharmacy practice in Nepal.Managing multimorbidity in primary care in patients with chronic respiratory conditions.Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study.An encapsulated juice powder concentrate improves markers of pulmonary function and cardiovascular risk factors in heavy smokersPolypharmacy and food-drug interactions among older persons: a review.Improving medication adherence in chronic obstructive pulmonary disease: a systematic reviewInhaled corticosteroids for chronic obstructive pulmonary disease.Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD.Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD.Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study.Working smarter not harder: Coupling implementation to de-implementation.Diseases Linked to Polypharmacy in Elderly Patients.Genuair(®) in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler.Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.Effect of dyspnea on frailty stages and related factors in Taiwanese men with COPD
P2860
Q28537875-8273959B-7A81-43A3-A2DE-D5EF10118BC4Q33736509-82C9F98C-E48A-4639-B0F9-8B55B0E0A5BCQ33824534-19F220C6-822A-4D30-9272-5A2666B46326Q34134884-A952E42C-8516-464B-8074-75C4C1FCDC18Q36036881-B1B56A3C-02C9-4E9A-97D2-BB1C54475372Q36151807-8BFFDCA1-3B0A-4C24-BFA1-149CA24A22A1Q36208427-5993BF93-4308-4E4D-AC1A-657ACAF8DD48Q36816740-CB3A067D-31F7-4A20-A550-EA63F91A9AD6Q37257970-259920BE-6326-438C-AF7C-15F085BFCCC1Q37354223-EE38F950-488A-445D-9F1C-1C7B61676B0BQ37718234-DEC3CE73-8B59-4D79-BDC0-92C8D79DB29AQ38060181-7E701A02-39EB-4D6A-B8FD-79CF5A13AFEBQ38153746-B32CF38C-2EF9-4CE7-9A9A-97A5BA643DA7Q38153757-24BF57FE-1DA0-41AA-BE7E-0CCC5FE4A23CQ38284373-C9B1E2A8-2339-496E-8286-47583D1B2BE5Q38586322-05E4B8AD-B239-471E-BB6C-EDDB673A09A0Q44450905-FCAA5AC6-5B52-4FE3-8BCC-6C68B723561FQ47104855-78FA4AF6-0716-46D8-8F04-8AF16DD7658EQ47555997-719216DE-6E24-4397-8143-F9B3CFF1B980Q47647923-12E23AC0-36C8-4B58-8603-8D95F12123A4Q47668522-670F4773-DF7E-46EF-9090-A9532ED3CD97Q49707624-A637BEEB-5735-4719-9F16-366698F80FB4Q51692765-2C3990C9-69D8-4E72-B45E-A5B2BD684B88Q55264356-B5B1725B-1380-4F9B-9875-DFE5E0BB0778Q55400944-9C594BDD-59D2-4BEB-875A-4AD23058844EQ58777670-762213A9-CA24-4782-A7B0-EE5A42EDF993
P2860
Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@ast
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@en
type
label
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@ast
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@en
prefLabel
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@ast
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@en
P2860
P50
P356
P1476
Determinants of polypharmacy a ...... obstructive pulmonary disease.
@en
P2860
P304
P356
10.2147/COPD.S24443
P407
P577
2011-09-26T00:00:00Z